menu search

ICPT / Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months

Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance. Read More
Posted: Mar 10 2023, 13:47
Author Name: Zacks Investment Research
Views: 112347

ICPT News  

Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know

By Zacks Investment Research
October 31, 2023

Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with more_horizontal

Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?

By Zacks Investment Research
September 27, 2023

Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?

Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help th more_horizontal

Why Intercept Pharmaceuticals Stock Is Skyrocketing Today

By The Motley Fool
September 26, 2023

Why Intercept Pharmaceuticals Stock Is Skyrocketing Today

The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share. more_horizontal

Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?

By InvestorPlace
September 26, 2023

Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?

Amid a rough day on Wall Street, Intercept Pharmaceuticals (NASDAQ: ICPT ) represented a bright spot, with shares swinging up 75% before slightly addi more_horizontal

Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal

By Proactive Investors
September 26, 2023

Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal

Intercept Pharmaceuticals (NASDAQ:ICPT) Inc shares surged 79% to $18.64 in late-morning trading on Tuesday after the biopharmaceutical company specia more_horizontal

Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium

By Market Watch
September 26, 2023

Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium

Shares of Intercept Pharmaceuticals Inc. ICPT, -0.38% were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acqui more_horizontal

Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y

By Zacks Investment Research
August 2, 2023

Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y

Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliv more_horizontal

Intercept Pharmaceuticals, Inc. (ICPT) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 2, 2023

Intercept Pharmaceuticals, Inc. (ICPT) Q2 2023 Earnings Call Transcript

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Execu more_horizontal


Search within

Pages Search Results: